GeoVax Labs Inc (GOVX)

[WOLDUMAR]

Grant Zeng: Building Biotech Wealth on Solid Platforms
http://www.equities.com/editors-desk/stocks/healthcare/grant-zeng-building-biotech-wealth-on-solid-platforms

GZ: I'd like to mention a very small company in a very specific area. GeoVax Labs, Inc. ($GOVX) is engaged in developing both therapeutic and preventative vaccines for HIV/AIDS. The company has candidates in clinical trials, and has already presented interim data—positive data—for both the preventive vaccines and the therapeutic vaccine.

The company has a specific and proprietary platform technology. As I have written, GeoVax's preventive HIV vaccine is among only five candidates, out of more than 90 vaccines entering HI Vaccine Trials Network Phase 1 testing, chosen to progress to Phase 2 clinical trials. The company's preventive vaccine is the only HIV vaccine for America/Europe entering an efficacy trial. Safety is good and efficacy is strong at this point.

Entering 2014, GeoVax plans to initiate a second Phase 1 trial with its second-generation therapeutic vaccine, and should enter a Phase 2 trial with its preventive vaccine in 2015. Those would be the next catalysts. I have an Outperform rating on GeoVax and a price target of $1.50/share.